Randomized study of endovascular therapy with versus without intravenous tissue plasminogen activator in acute stroke with ICA and M1 occlusion - A prospective, multicenter, randomized trial

Conditions

Acute ischemic stroke

Suzuki K, Matsumaru Y, Takeuchi M, Morimoto M, Kanazawa R, Takayama Y, Kamiya Y, Shigeta K, Okubo S, Hayakawa M, Ishii N, Koguchi Y, Takigawa T, Inoue M, Naito H, Ota T, Hirano T, Kato N, Ueda T, Iguchi Y, Akaji K, Tsuruta W, Miki K, Fujimoto S, Higashida T, Iwasaki M, Aoki J, Nishiyama Y, Otsuka T, Kimura K, SKIP study Investigators.

2023-09-073 citations

10.1016/j.jns.2023.120797

Intravenous Thrombolysis Increases the First Pass Effect for Large Vessel Occlusion Treated With Mechanical Thrombectomy

Yuki Kamiya, Kentaro Suzuki, Yoshifumi Miyauchi, Ayako Kuriki, Keita Mizuma et al. (9 authors)

Stroke Vascular and Interventional Neurology2023-07-113 citations

10.1161/svin.122.000577

MR CLEAN-NO IV: intravenous treatment followed by endovascular treatment versus direct endovascular treatment for acute ischemic stroke caused by a proximal intracranial occlusion-study protocol for a randomized clinical trial.

Treurniet KM, LeCouffe NE, Kappelhof M, Emmer BJ, van Es ACGM, Boiten J, Lycklama GJ, Keizer K, Yo LSF, Lingsma HF, van Zwam WH, de Ridder I, van Oostenbrugge RJ, van der Lugt A, Dippel DWJ, Coutinho JM, Roos YBWEM, Majoie CBLM, MR CLEAN-NO IV Investigators.

2021-02-1545 citations

10.1186/s13063-021-05063-5

Effect of Mechanical Thrombectomy Without vs With Intravenous Thrombolysis on Functional Outcome Among Patients With Acute Ischemic Stroke

Kentaro Suzuki, Yuji Matsumaru, Masataka Takeuchi, Masafumi Morimoto, Ryuzaburo Kanazawa et al. (31 authors)

JAMA2021-01-19517 citations

10.1001/jama.2020.23522

The randomized study of endovascular therapy with versus without intravenous tissue plasminogen activator in acute stroke with ICA and M1 occlusion (SKIP study)

Kentaro Suzuki, Kazumi Kimura, Masataka Takeuchi, Masafumi Morimoto, Ryuzaburo Kanazawa et al. (25 authors)

International Journal of Stroke2019-03-2958 citations

10.1177/1747493019840932

Interventions

Endovascular therapy Endovascular therapy intravenous tissue plasminogen

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Patients of from 18 to 85 years old 2.Continued clinical symptoms in patoents with acute cerebral infarction 3.Pre mRS within 2 4.Patients with ICA or M1 occlusion and be able to puncture within 4 hours. 5.DWI-ASPECTS more than 5 or ASPECTS more than 6 at pre endovascular therapy 6.NIHSS more than 6 7.Research consent have been obtained in writing from the person or alternative person

Exclusion criteria

Exclusion criteria: 1.Patients with a hypersensitivity to contrast 2.Past history of puncture artery hemostasis 3.Patients with severe urine function 4.A lactating or pregnant patients 5.Patient expected life expectancy within 90 days 6.Ineligible for tPA therapy patients 7.Patient deemed unfit to conduct this testing responsible physician or trial division

Design outcomes

Primary

Measure	Time frame
Rate of Modified Rankin Scale 0-2 at 90 days after onset. (Noninferior)	—

Secondary

Measure	Time frame
Rate of asymptomatic and symptomatic intracranial hemorrhage at 24 hours after onset.	—

Countries

Japan

Contacts

Public ContactKENTARO SUZUKI

Nippon Medical School Neurological Science

kentarow@nms.ac.jp03-3822-2131

Outcome results

None listed